Yan Leyfman: Practice-Changing Data in Head and Neck Cancer
Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on LinkedIn:
“Practice-Changing Data in Head and Neck Cancer
The phase 3 KEYNOTE-689 trial shows that adding perioperative pembrolizumab (before and after surgery) to standard care significantly improves event-free survival in patients with locally advanced head and neck squamous cell carcinoma (HNSCC).
36-month EFS (CPS ≥10):
59.8% with pembrolizumab vs. 45.9% with standard care
HR: 0.66 | P = 0.004
Pembrolizumab didn’t delay surgery and no new safety signals emerged.
Conclusion: Immunotherapy before and after surgery may be a new frontier for resectable HNSCC.”
Title: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
Authors: Ravindra Uppaluri, Robert Haddad, Yungan Tao, Christophe Le Tourneau, Nancy Lee, William Westra, Rebecca Chernock, Makoto Tahara, Kevin Harrington, Arkadiy Klochikhin, Irene Braña, Gustavo Vasconcelos Alves, Brett Hughes, Marc Oliva, Iane Pinto Figueiredo Lima, Tsutomu Ueda, Tomasz Rutkowski, Ursula Schroeder, Paul-Stefan Mauz, Thorsten Fuereder, Simon Laban, Nobuhiko Oridate, Aron Popovtzer, Nicolas Mach, Yevhen Korobko, Diogo Alpuim Costa, Anupama Hooda-Nehra, Cristina Rodriguez, R. Bryan Bell, Cole Manschot, Kimberly Benjamin, Burak Gumuscu, Douglas Adkins
You can read the Full Article on The New England Journal of Medicine
More posts featuring Yan Leyfman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023